Celecoxib or naproxen treatment does not benefit depressive symptoms in persons age 70 and older: Findings from a randomized controlled trial

American Journal of Geriatric Psychiatry

Volumn 20, Issue 6, 2012, Pages 505-513

  Fields, Cynthia ^a   Drye, Lea ^a   Vaidya, Vijay ^a   Lyketsos, Constantine ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti inflammatory treatment; celecoxib; late life depression; naproxen

Indexed keywords

CELECOXIB; NAPROXEN; PLACEBO;

AGE; AGED; ALZHEIMER DISEASE; ARTICLE; COGNITION; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FAMILY HISTORY; FEMALE; FOLLOW UP; GERIATRIC DEPRESSION SCALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; RANDOMIZED CONTROLLED TRIAL;

EID: 84861460724     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1097/JGP.0b013e318227f4da     Document Type: Article

References (51)

1. Smith RS: Themacrophage theory of depression. Med Hypotheses 1991; 35(4):298-306
2. Maes M, Scharpe S, Meltzer HY, et al: Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary- adrenal axis in severe depression. Psychiatry Res 1993; 49(1):11-27 (Pubitemid 23329244)
3. Maes M, Bosmans E, De Jongh R, et al: Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997; 9(11):853-858 (Pubitemid 27494150)
4. van West D, Maes M: Activation of the inflammatory response system: a new look at the etiopathogenesis of major depression. Neuro Endocrinol Lett 1999; 20(1/2):11-17
5. Schiepers OJ, Wichers MC, Maes M: Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29(2):201-217 (Pubitemid 40202906)
6. Linnoila M, Whorton AR, Rubinow DR, et al: CSF prostaglandin levels in depressed and schizophrenic patients. Arch Gen Psychiatry 1983; 40(4):405-406 (Pubitemid 13118574)
7. Lieb J, Karmali R, Horrobin D: Elevated levels of prostaglandin E2 and thromboxane B2 in depression. Prostaglandins Leukot Med 1983; 10(4):361-367 (Pubitemid 13162267)
8. Calabrese JR, Skwerer RG, Barna B, et al: Depression, immunocompetence, and prostaglandins of the E series. Psychiatry Res 1986; 17(1):41-47 (Pubitemid 16212700)
9. Ohishi K, Ueno R, Nishino S, et al: Increased level of salivary prostaglandins in patients with major depression. Biol Psychiatry 1988; 23(4):326-334 (Pubitemid 18043535)
10. Nishino S, Ueno R, Ohishi K, et al: Salivary prostaglandin concentrations: possible state indicators for major depression. Am J Psychiatry 1989; 146(3):365-368 (Pubitemid 19078202)
11. Zorrilla EP, Luborsky L, McKay JR, et al: The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun 2001; 15(3):199-226 (Pubitemid 33070955)
12. Bruce TO: Comorbid depression in rheumatoid arthritis: pathophysiology and clinical implications. Curr Psychiatry Rep 2008; 10(3):258-264
13. Gold SM, Irwin MR: Depression and immunity: inflammation and depressive symptoms in multiple sclerosis. Neurol Clin 2006; 24(3):507-519 (Pubitemid 44108542)
14. Musselman DL, Lawson DH, Gumnick JF, et al: Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344(13):961-966 (Pubitemid 32240314)
15. Capuron L, Gumnick JF, Musselman DL, et al: Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002; 26(5):643-652 (Pubitemid 34260983)
16. Yirmiya R: Endotoxin produces a depressive-like episode in rats. Brain Res 1996; 711(1/2):163-174 (Pubitemid 26080239)
17. Yirmiya R, Pollak Y, Barak O, et al: Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacology 2001; 24(5):531-544 (Pubitemid 32244314)
18. Dantzer R, Bluthe RM, Laye S, et al: Cytokines and sickness behavior. Ann N Y Acad Sci 1998; 840:586-590 (Pubitemid 28302084)
19. Yirmiya R, Barak O, Avitsur R, et al: Intracerebral administration of mycoplasma fermentans produces sickness behavior: role of prostaglandins. Brain Res 1997; 749(1):71-81 (Pubitemid 27096456)
20. Blazer DG: Depression in late life: review and commentary. J Gerontol A Biol Sci Med Sci 2003; 58(3):249-265 (Pubitemid 36307597)
21. Alexopoulos GS: Depression in the elderly. Lancet 2005; 365(9475):1961-1970 (Pubitemid 40797508)
22. Tiemeier H: Biological risk factors for late life depression. Eur J Epidemiol 2003; 18(8):745-750 (Pubitemid 37039971)
23. Dantzer R, O'Connor JC, Freund GG, et al: From inflammation to sickness and depression:when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9(1):46-56 (Pubitemid 350295688)
24. Bremmer MA, Beekman AT, Deeg DJ, et al: Inflammatory markers in late-life depression: results from a population-based study. J Affect Disord 2008; 106(3):249-255
25. Tiemeier H, Hofman A, van Tuijl HR, et al: Inflammatory proteins and depression in the elderly. Epidemiology 2003; 14(1): 103-107 (Pubitemid 40416821)
26. Penninx BW, Kritchevsky SB, Yaffe K, et al: Inflammatory markers and depressed mood in older persons: results from the health, aging and body composition study. Biol Psychiatry 2003; 54(5): 566-572 (Pubitemid 37289443)
27. Dimopoulos N, Piperi C, Psarra V, et al: Increased plasma levels of 8-iso-PGF2alpha and IL-6 in an elderly population with depression. Psychiatry Res 2008; 161(1):59-66
28. Thomas AJ, Davis S, Morris C, et al: Increase in interleukin-1beta in late-life depression. Am J Psychiatry 2005; 162(1):175-177
29. van den Biggelaar AH, Gussekloo J, de Craen AJ, et al: Inflammation and interleukin-1 signaling network contribute to depressive symptoms but not cognitive decline in old age. Exp Gerontol 2007; 42(7):693-701 (Pubitemid 46756098)
30. Milaneschi Y, Corsi AM, Penninx BW, et al: Interleukin-1 receptor antagonist and incident depressive symptoms over 6 years in older persons: the InCHIANTI study. Biol Psychiatry 2009; 65(11): 973-978
31. Godbout JP, Moreau M, Lestage J, et al: Aging exacerbates depressive-like behavior in mice in response to activation of the peripheral innate immune system. Neuropsychopharmacology 2008; 33(10):2341-2351
32. Ye SM, Johnson RW: Increased interleukin-6 expression by microglia from brain of aged mice. J Neuroimmunol 1999; 93(1/2):139-148 (Pubitemid 29051559)
33. Ye SM, Johnson RW: An age-related decline in interleukin-10 may contribute to the increased expression of interleukin-6 in brain of aged mice. Neuroimmunomodulation 2001; 9(4):183-192 (Pubitemid 34195776)
34. Suleyman H, Demircan B, Karagoz Y: Anti-inflammatory and side effects of cyclooxygenase inhibitors. Pharmacol Rep 2007; 59(3):247-258 (Pubitemid 47299726)
35. Botting RM: Inhibitors of cyclooxygenases: mechanisms, selectivity and uses. J Physiol Pharmacol 2006; 57(suppl 5):113-124 (Pubitemid 46569788)
36. Vane JR, Bakhle YS, Botting RM: Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38:97-120 (Pubitemid 28231490)
37. Casolini P, Catalani A, Zuena AR, et al: Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat. J Neurosci Res 2002; 68(3):337-343 (Pubitemid 34462539)
38. Myint AM, Steinbusch HW, Goeghegan L, et al: Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression. Neuroimmunomodulation 2007; 14(2):65-71 (Pubitemid 47442983)
39. Guo JY, Li CY, Ruan YP, et al: Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain. Eur J Pharmacol 2009; 612(1-3):54-60
40. Muller N, Schwarz MJ, Dehning S, et al: The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006; 11(7): 680-684 (Pubitemid 43989814)
41. Akhondzadeh S, Jafari S, Raisi F, et al Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 2009; 26(7):607-611
42. Nery FG, Monkul ES, Hatch JP, et al: Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 2008; 23(2):87-94 (Pubitemid 351359580)
43. Brunello N, Alboni S, Capone G, et al: Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression. Int Clin Psychopharmacol 2006; 21(4):219-225 (Pubitemid 43740299)
44. Mendlewicz J, Kriwin P, Oswald P, et al: Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. Int Clin Psychopharmacol 2006; 21(4):227-231 (Pubitemid 43740300)
45. Yesavage JA: Geriatric Depression Scale. Psychopharmacol Bull 1988; 24(4):709-711
46. ADAPT Research Group,Martin BK, Szekely C, et al: Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 2008; 65(7):896-905
47. ADAPT Research Group Lyketsos CG, Breitner JC, et al Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 2007; 68(21):1800-1808 (Pubitemid 46791392)
48. Teng EL, Chui HC: The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry 1987; 48(8):314-318 (Pubitemid 17138128)
49. Yesavage JA, Brink TL, Rose TL, et al: Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982-1983; 17(1):37-49 (Pubitemid 13123113)
50. Debruyne H, Van Buggenhout M, Le Bastard N, et al: Is the Geriatric Depression Scale a reliable screening tool for depressive symptoms in elderly patients with cognitive impairment? Int J Geriatr Psychiatry 2009; 24(6):556-562
51. Wancata J, Alexandrowicz R, Marquart B, et al: The criterion validity of the Geriatric Depression Scale: a systematic review. Acta Psychiatr Scand 2006; 114(6):398-410 (Pubitemid 44707067)